National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Atezolizumab (Tecentriq®) for triple-negative breast cancer.

Atezolizumab in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.


NCPE Assessment Process Complete
Rapid review commissioned 03/07/2019
Rapid review completed 19/07/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 30/07/2019
Pre-submission consultation with Applicant 07/10/2019
Initial submission received from Applicant 09/12/2019
Complete submission received from Applicant 13/01/2020
Preliminary review sent to Applicant 05/05/2020
NCPE assessment re-commenced 29/05/2020
Factual accuracy check sent to Applicant 06/08/2020
NCPE assessment re-commenced 14/08/2020
NCPE assessment completed 01/09/2020
NCPE assessment outcome The NCPE recommends that atezolizumab (Tecentriq®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.